Literature DB >> 15721414

Impact of tumor volume-directed involved field radiation therapy integrated in the management of recurrent ovarian cancer.

K V Albuquerque1, R Singla, R K Potkul, D M Smith, S Creech, S Lo, B Emami.   

Abstract

OBJECTIVES: Assess the role of involved field radiation therapy (IFRT) in recurrent ovarian cancer.
METHODS: Thirty-five patients with a diagnosis of epithelial ovarian cancer received radiation therapy at LUMC between 1991 and 2001. Of these, 20 received tumor volume-directed IFRT for localized extraperitoneal recurrences (either as consolidation following debulking surgery or as attempted salvage if unresectable) and form the basis of this report. All patients were heavily pretreated with multiple chemotherapy regimens. Eleven patients had optimal debulking of their recurrences prior to radiation. IFRT was primarily with external beam (median dose 50.4 Gy). Appropriate statistical analyses evaluated association among disease-free (DFS), overall survival (OS), local recurrence-free (LRFS), and various prognostic factors. LRFS was defined as freedom from in-field recurrences and was considered as a measure of effectiveness of radiotherapy.
RESULTS: Of 20 patients, 17 had a complete response after RT. The actuarial LRFS, OS, and DFS at 5 years from date of radiation were 66%, 34%, and 34%, respectively. The LRFS at 3 years was 89% for those with optimal resection vs. 42% for those with gross residual/unresectable tumor, which was significantly better (P = 0.04). The corresponding 3-year DFS was 72% vs. 22% and 5-year OS was 50% vs. 19%, respectively. Acute complication of RT was mild, half had Grade 1-2 gastrointestinal (GI) toxicity, three patients had Grade 3-4 late GI effects.
CONCLUSION: IFRT is effective in controlling localized recurrences of ovarian cancer, especially after they are optimally debulked (89% local control and 50% 5-year overall survival in this subgroup), and is relatively well tolerated in these heavily pretreated patients.

Entities:  

Mesh:

Year:  2005        PMID: 15721414     DOI: 10.1016/j.ygyno.2004.11.008

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  11 in total

1.  Treatment-interval associated effect of irradiation on locoregionally-relapsed ovarian cancer.

Authors:  Motoaki Saito; Chihiro Kanehira; Seiji Isonishi
Journal:  Mol Clin Oncol       Date:  2014-06-16

2.  Involved-field radiation therapy for locoregionally recurrent ovarian cancer.

Authors:  Aaron P Brown; Anuja Jhingran; Ann H Klopp; Kathleen M Schmeler; Pedro T Ramirez; Patricia J Eifel
Journal:  Gynecol Oncol       Date:  2013-05-04       Impact factor: 5.482

Review 3.  Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future.

Authors:  Emma C Fields; William P McGuire; Lilie Lin; Sarah M Temkin
Journal:  Front Oncol       Date:  2017-08-21       Impact factor: 6.244

4.  Metastatic Ovarian Cancer Presenting as Inflammatory Breast Cancer: A Case Report.

Authors:  Mohammad Abu-Tineh; Hind Elmalik; Mohamed A Yassin
Journal:  Case Rep Oncol       Date:  2020-07-28

5.  Involved-field radiation therapy for selected cases of recurrent ovarian cancer.

Authors:  Nalee Kim; Jee Suk Chang; Sang Wun Kim; Gun Min Kim; Jung Yun Lee; Yong Bae Kim
Journal:  J Gynecol Oncol       Date:  2019-09       Impact factor: 4.401

6.  Annealing-modulated nanoscintillators for nonconventional X-ray activation of comprehensive photodynamic effects in deep cancer theranostics.

Authors:  Yao-Chen Chuang; Chia-Hui Chu; Shih-Hsun Cheng; Lun-De Liao; Tsung-Sheng Chu; Nai-Tzu Chen; Arthur Paldino; Yu Hsia; Chin-Tu Chen; Leu-Wei Lo
Journal:  Theranostics       Date:  2020-05-20       Impact factor: 11.556

7.  Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers.

Authors:  David S Lakomy; Diana L Urbauer; Shannon N Westin; Lilie L Lin
Journal:  Clin Transl Radiat Oncol       Date:  2019-12-28

8.  Stereotactic Body Radiation Therapy: A Versatile, Well-Tolerated, and Effective Treatment Option for Extracranial Metastases From Primary Ovarian and Uterine Cancer.

Authors:  Nima Aghdam; Michael C Repka; Mary McGunigal; Abby Pepin; Ima Paydar; Sonali Rudra; Nitika Paudel; Monica Pernia Marin; Simeng Suy; Sean P Collins; Willard Barnes; Brian T Collins
Journal:  Front Oncol       Date:  2020-12-10       Impact factor: 6.244

9.  Epithelial ovarian cancer: definitive radiotherapy for limited recurrence after complete remission had been achieved with aggressive front-line therapy.

Authors:  Katsuya Yahara; Takayuki Ohguri; Hajime Imada; Shinsaku Yamaguchi; Toshinori Kawagoe; Yusuke Matsuura; Toru Hachisuga; Yukunori Korogi
Journal:  J Radiat Res       Date:  2012-11-23       Impact factor: 2.724

10.  Clinical analysis of conformal and intensity-modulated radiotherapy in patients with recurrent ovarian cancer.

Authors:  Hua Yang; Kaishuo Zhang; Zi Liu; Tao Wang; Fan Shi; Jin Su; Jintao Zhang; Juanyue Liu; Li Dai
Journal:  Sci Rep       Date:  2020-10-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.